Cargando…

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study

BACKGROUND: Whether plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) levels is a predictor for cardiovascular outcomes has currently been controversial. No data is currently available regarding the relation of PCSK9 to cardiovascular metabolic markers (CVMMs) and major adverse cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Jia, Liu, Ming-Ming, Jin, Jing-Lu, Cao, Ye-Xuan, Guo, Yuan-Lin, Wu, Na-Qiong, Zhu, Cheng-Gang, Dong, Qian, Sun, Jing, Xu, Rui-Xia, Li, Jian-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7541318/ https://www.ncbi.nlm.nih.gov/pubmed/33023603 http://dx.doi.org/10.1186/s12933-020-01142-0

Ejemplares similares

Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
por: Cao, Ye-Xuan, et al.
Publicado: (2019)

Association of PCSK9 plasma levels with metabolic patterns and coronary atherosclerosis in patients with stable angina
por: Caselli, Chiara, et al.
Publicado: (2019)

NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study
por: Peng, Jia, et al.
Publicado: (2022)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Leptin and PCSK9 concentrations are associated with vascular endothelial cytokines in patients with stable coronary heart disease
por: Wang, Qiang, et al.
Publicado: (2022)

Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases
por: Girona, Josefa, et al.
Publicado: (2016)

Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease
por: Xu, Rui-Xia, et al.
Publicado: (2014)

Depression and cardiovascular risk—association among Beck Depression Inventory, PCSK9 levels and insulin resistance
por: Macchi, C., et al.
Publicado: (2020)

Relationship between Circulating PCSK9 and Markers of Subclinical Atherosclerosis—The IMPROVE Study
por: Coggi, Daniela, et al.
Publicado: (2021)

Circulating PCSK9 Level and Risk of Cardiovascular Events and Death in Hemodialysis Patients
por: Hwang, Hyeon Seok, et al.
Publicado: (2020)

The predictive utility of circulating PCSK9 levels on diabetes mellitus
por: Peng, Jia, et al.
Publicado: (2021)

Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C
por: Li, Sha, et al.
Publicado: (2016)

A Genetic Approach to the Association Between PCSK9 and Sepsis
por: Feng, QiPing, et al.
Publicado: (2019)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

Impact of bariatric surgery on circulating PCSK9 levels as a marker of cardiovascular disease risk: a meta-analysis
por: Jamialahmadi, Tannaz, et al.
Publicado: (2022)

Liraglutide downregulates hepatic LDL receptor and PCSK9 expression in HepG2 cells and db/db mice through a HNF-1a dependent mechanism
por: Yang, Sheng-Hua, et al.
Publicado: (2018)

Real-world data on metabolic effects of PCSK9 inhibitors in a tertiary care center in patients with and without diabetes mellitus
por: Fischer, Laurenz T., et al.
Publicado: (2021)

Enhanced circulating PCSK9 concentration by berberine through SREBP-2 pathway in high fat diet-fed rats
por: Jia, Yan-Jun, et al.
Publicado: (2014)

Can metformin stabilize PCSK9 level in stable coronary artery disease patients treated with statins?
por: Shek, Aleksandr B., et al.
Publicado: (2019)

Circulating PCSK9 Linked to Dyslipidemia in Lebanese Schoolchildren
por: Azar, Yara, et al.
Publicado: (2022)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

Circulating concentrations of GLP-1 are associated with coronary atherosclerosis in humans
por: Piotrowski, Katja, et al.
Publicado: (2013)

The Concentration of PCSK9-Lp(a) Complexes and the Level of Blood Monocytes in Males with Coronary Atherosclerosis
por: Filatova, Anastasiia Yu., et al.
Publicado: (2023)

PCSK9 Inhibition During the Inflammatory Stage of SARS-CoV-2 Infection
por: Navarese, Eliano P., et al.
Publicado: (2023)

Association of circulating proprotein convertase subtilisin/kexin type 9 concentration, prothrombin time and cardiovascular outcomes: a prospective cohort study
por: Peng, Jia, et al.
Publicado: (2021)

Association of PCSK9 with inflammation and platelet activation markers and recurrent cardiovascular risks in STEMI patients undergoing primary PCI with or without diabetes
por: Song, Li, et al.
Publicado: (2022)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

Sex difference in circulating PCSK9 and its clinical implications
por: Jia, Fang, et al.
Publicado: (2022)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

PCSK9 as a therapeutic target for cardiovascular disease
por: Zhang, Pei-Ying
Publicado: (2017)

Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors
por: Gai, Min-Tao, et al.
Publicado: (2021)

Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study
por: Zhang, Hui-Wen, et al.
Publicado: (2020)

PCSK 9 gain-of-function mutations (R496W and D374Y) and clinical cardiovascular characteristics in a cohort of Turkish patients with familial hypercholesterolemia
por: Kaya, Esra, et al.
Publicado: (2017)

PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR
por: Rogacev, Kyrill S., et al.
Publicado: (2016)

Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction
por: Gao, Jing, et al.
Publicado: (2021)

Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction
por: Zhang, Zhong, et al.
Publicado: (2019)

Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway
por: Laugsand, Lars E., et al.
Publicado: (2016)

Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study
por: Jin, Jing-Lu, et al.
Publicado: (2020)

Predictive values of coronary artery calcium and arterial stiffness for long‐term cardiovascular events in patients with stable coronary artery disease
por: Limpijankit, Thosaphol, et al.
Publicado: (2022)

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qpqknb18ggg9hfhc2tq30760sg